Onconox’s Inhaled Radiosensitizer: Advancing Radiotherapy in Stage I and Stage III NSCLC

Summary

Non-small-cell lung cancer, NSCLC, remains the leading cause of cancer mortality worldwide. Despite advances in lung cancer radiotherapy, stereotactic body radiotherapy, SBRT, chemoradiotherapy, and immunotherapy, survival outcomes in both Stage I NSCLC and Stage III NSCLC remain suboptimal.

Stage I NSCLC patients treated with SBRT still experience distant metastasis rates approaching 25%, while Stage III NSCLC patients receiving concurrent chemoradiotherapy followed by durvalumab demonstrate five-year overall survival of only approximately 30%. Radiation pneumonitis and pulmonary toxicity limit dose intensification and therapeutic escalation.

Clinically effective radiosensitizers are scarce in lung cancer, and historical systemic radiosensitizers failed due to toxicity. Onconox’s inhaled radiosensitizer platform is designed to enhance tumor radiosensitivity directly within lung tissue while minimizing systemic exposure. This strategy addresses a major unmet need in NSCLC radiotherapy and chemoradiotherapy.

The Global Burden of Non-Small-Cell Lung Cancer (NSCLC)

Lung cancer remains the most common cause of cancer death globally, with approximately 2.5 million new cases and over 1.8 million deaths reported in 2022.¹

Non-small-cell lung cancer accounts for approximately 77–87% of all lung cancers.² ³ In the United States, the American Cancer Society projects 229,410 new lung cancer cases and 124,990 deaths in 2026, with an overall five-year survival rate of just 28%.²

For localized NSCLC, five-year survival reaches 65%. However, 43% of patients present with metastatic disease, where five-year survival falls to 10%.⁴ Lung cancer screening remains underutilized, with only 18.2% of high-risk individuals screened in 2022.⁴

Importantly, many patients with NSCLC are not surgical candidates. Only 20.7% undergo surgery, while a substantial proportion receive definitive lung cancer radiotherapy or chemoradiotherapy.³ ⁴ These patients represent the core population who may benefit from a next-generation radiosensitizer delivered directly to lung tumors.

Stage I NSCLC: SBRT Improves Local Control, But Metastatic Risk Persists

For medically inoperable Stage I NSCLC, conventional fractionated lung cancer radiotherapy historically delivered poor outcomes, with five-year survival of 10–22% and local control rates of 50–60%.⁵

Stereotactic body radiotherapy, SBRT, has transformed early-stage NSCLC management by delivering ablative doses in 3–5 fractions, improving local tumor control and reducing treatment burden.⁵ SBRT has become the standard for medically inoperable Stage I NSCLC.

However, even with SBRT:

• Five-year overall survival reaches 74.2%

• Five-year progression-free survival is 71.9%

• Disease progression still occurs in 21.3% of patients, primarily due to distant metastasis⁶

A separate multicenter cohort demonstrated five-year progression-free survival of 50.8%, with distant metastasis in 25.6% of patients treated with SBRT for Stage I NSCLC.⁷

These data underscore a critical reality in early-stage non-small-cell lung cancer: while SBRT achieves strong local control, micrometastatic disease and systemic relapse remain major drivers of mortality.

Quality-of-life outcomes favor SBRT over surgery, with QOL remaining stable following stereotactic lung radiotherapy.⁸ However, improved radiosensitization strategies could further reduce recurrence risk and enhance long-term survival in Stage I NSCLC.

Stage III NSCLC: Chemoradiotherapy and Immunotherapy Still Leave Major Gaps

Stage III NSCLC represents 20–30% of new diagnoses and is typically managed with concurrent chemoradiotherapy, CCRT, followed by durvalumab consolidation immunotherapy.

Despite this multimodal treatment approach:

• Five-year overall survival remains approximately 32%⁹

• Locoregional failure rates are approximately 38.5%⁹

• Real-world data show 52% of patients progress despite durvalumab¹⁰

• Isolated distant metastasis is the most common failure pattern¹⁰

Even with advances in intensity-modulated radiotherapy and immunotherapy, Stage III non-small-cell lung cancer continues to carry high mortality.

Pulmonary toxicity remains a limiting factor. Radiation pneumonitis occurs in 18–50% of patients receiving chemoradiotherapy, with grade ≥3 events in 4–8%.¹¹ ¹² This restricts radiation dose escalation and intensification of chemoradiotherapy regimens.

An inhaled radiosensitizer that enhances tumor response without increasing pulmonary toxicity represents a rational innovation in Stage III NSCLC management.

The Unmet Need for Effective Radiosensitizers in NSCLC

Radiotherapy is used in approximately 70% of cancer patients.¹³ However, clinically approved radiosensitizers in lung cancer are extremely limited.

Early hypoxic radiosensitizers such as misonidazole failed due to neurotoxicity.¹³ Second-generation agents improved pharmacologic properties but failed to demonstrate meaningful survival benefit.¹³

A 2021 review identified only a small number of small-molecule radiosensitizers in clinical development, none approved specifically for NSCLC radiotherapy.¹³

This lack of effective radiosensitizers in non-small-cell lung cancer represents a major therapeutic gap.

Why Inhaled Radiosensitization Is a Strategic Advantage in Lung Cancer

Inhaled therapy provides unique pharmacologic and oncologic advantages in NSCLC:

• Bypasses first-pass metabolism

• Achieves high local lung bioavailability

• Enables rapid drug accumulation at tumor sites

• Minimizes systemic toxicity¹⁴

Inhaled anticancer therapies may also access pulmonary lymphatic drainage, potentially reducing micrometastatic spread.¹⁴

Preclinical models demonstrate that inhaled nanoparticle-based chemotherapy achieves higher intratumoral concentrations and improved synergy with radiotherapy compared with intravenous administration.¹⁵ Inhaled nanoparticle radiosensitization strategies enhanced tumor response while minimizing systemic toxicity in NSCLC models.¹⁵

These findings support the strategic rationale for an inhaled radiosensitizer platform targeting lung tumors directly during radiotherapy or chemoradiotherapy.

Why Onconox Is Leading with NSCLC

Onconox is prioritizing Stage I NSCLC and Stage III NSCLC for five key reasons:

1. Large population receiving lung cancer radiotherapy or chemoradiotherapy³

2. High recurrence rates despite SBRT and chemoradiotherapy⁶ ¹⁰

3. Dose-limiting pulmonary toxicity, including radiation pneumonitis¹¹ ¹²

4. Compatibility with SBRT fractionation and daily chemoradiotherapy schedules

5. Absence of approved, lung-targeted radiosensitizers¹³

Our inhaled radiosensitizer platform is designed to enhance DNA damage within hypoxic tumor regions, improve local tumor control, reduce distant metastasis, and avoid systemic toxicity associated with intravenous agents.

By focusing on NSCLC radiotherapy intensification through inhaled delivery, we are addressing one of oncology’s largest and most persistent unmet needs.

Conclusion

Non-small-cell lung cancer remains the world’s deadliest cancer. Despite improvements in SBRT, chemoradiotherapy, and immunotherapy, both Stage I NSCLC and Stage III NSCLC continue to experience substantial recurrence and mortality.

The scarcity of effective radiosensitizers, combined with dose-limiting pulmonary toxicity such as radiation pneumonitis, creates a compelling opportunity for innovation in lung cancer radiotherapy.

Onconox’s inhaled radiosensitizer platform is specifically designed to enhance tumor radiosensitivity in NSCLC while preserving patient safety and quality of life. By targeting the largest radiotherapy-treated population in oncology, we aim to redefine outcomes in early-stage and locally advanced non-small-cell lung cancer.

References

1. International Agency for Research on Cancer. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2024.

2. American Cancer Society. Cancer Facts & Figures 2026. Atlanta, GA: American Cancer Society; 2026.

3. American Cancer Society. Cancer treatment and survivorship statistics 2026. CA Cancer J Clin. 2026.

4. American Cancer Society. Lung cancer survival rates and screening statistics. CA Cancer J Clin. 2026.

5. Sun H, Wang H, Wei Y, et al. Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable early-stage NSCLC. Cost Eff Resour Alloc. 2023;21:46.

6. [Single-institution SBRT outcomes study]. J Thorac Oncol Clin Res Rep. 2025.

7. [Multicenter SBRT survival analysis]. 2024 cohort study.

8. Iovoli AJ, Yu B, Ma SJ, et al. Quality of life after stereotactic body radiation therapy or surgery for early-stage NSCLC: a systematic review. JTO Clin Res Rep. 2022;3:100417.

9. [Stage III review of chemoradiotherapy outcomes]. 2026 review article.

10. [Real-world PACIFIC regimen analysis]. 2025 study.

11. [Durvalumab pneumonitis meta-analysis]. Front Oncol. 2024.

12. [Meta-analysis of radiation pneumonitis incidence]. 2024.

13. Wardman P. Chemical radiosensitizers for cancer therapy: clinical development and challenges. Front Pharmacol. 2021;12:660310.

14. Inhaled anticancer drug delivery review. Molecules. 2021;26:4447.

15. Nanoparticle-based inhaled radiosensitization strategies in NSCLC. Pharmaceutics. 2021.